PA-STRATUS-MATERIALS
25.6.2024 15:02:03 CEST | Business Wire | Press release
Stratus Materials Inc., a company focused on the development and commercialization of advanced cathode active materials (CAMs) for lithium-ion batteries, today announced that its first-generation LXMO CAM material has achieved a significant milestone associated with cycling durability in electric vehicle applications.
This month, LXMO-containing pouch cells surpassed 1,000 full depth-of-discharge cycles while maintaining greater than 80% of their initial capacity, a common goal across the EV battery industry. The 3rd party-built cells used standard cell and electrode designs, employing a natural graphite anode and an electrolyte of standard industry components, to work in conjunction with the Stratus cathode material. The cells in the test group maintained 82-86% of their initial capacity and are projected to exceed 1,200 cycles before reaching 80% of their initial capacities. At the same 1,000-cycle point, the average discharge voltage of the cells maintained approximately 97%, dropping only 0.1 V from their initial values. The excellent capacity and voltage stability of the cells surpass the energy retention of many commercial materials in use today.
Jay Whitacre, CEO & CTO of Stratus Materials (and Professor at Carnegie Mellon University), said: “These cells have been cycling for the last 10 months and clearly demonstrate that our proprietary materials are able to meet EV industry durability needs. To our knowledge this is the first time such minimal loss in cell voltage has been documented for this class of materials. The Stratus team looks forward to building upon these strong technical results as we improve, commercialize, and scale production in the coming quarters.”
Stratus products are in the lithium-rich, manganese-rich (LMR) category of cathode active materials. LMR cathodes have garnered significant interest in the Li-ion battery and EV industries due to several highly promising attributes including high energy density, low cost, and high safety. However, despite being in development around the world for over two decades, LMRs have not yet been commercially deployed because of several persistent technical challenges – primarily the voltage and capacity instability issues that Stratus Materials has largely overcome, as demonstrated by its latest results. With its continued technological progress, Stratus Materials is focused on enabling the first fully functional, LMR-class CAMs that are suitable for full-scale, commercial use.
Scott Pearson, President & CCO, added: “We are thrilled to show that our first-generation LXMO material can exceed this EV cell durability target while also delivering a set of highly compelling advantages versus incumbent CAMs. We expect that this proof point will be one of many that we will be offering to our industry partners and customers.”
Stratus is currently producing materials on its existing pre-pilot production line in Pittsburgh, Pennsylvania and has ongoing sampling efforts underway with many of the leading companies in the EV and EV battery industries. As previously announced, the company will be increasing its production capabilities from pre-pilot to pilot scale later in 2024.
ABOUT STRATUS MATERIALS
Stratus Materials (www.stratusmaterials.com) is a U.S. based company focused on the development and commercialization of next-generation cathode active materials (CAMs) for lithium-ion batteries. Our mission is to disrupt the CAM supply chain by offering materials with a game-changing combination of performance, safety, and cost. Stratus is primarily focusing its cobalt-free LXMOTM cathode products on light- and medium-duty electric vehicles and other applications with similar requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625022288/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
